ISPOR - EPH138 Post-Marketing Adverse Events of Oncology Medications with Breakthrough Therapy Designation Correlated with Time on Market and Market Share

EPH138 Post-Marketing Adverse Events of Oncology Medications with Breakthrough Therapy Designation Correlated with Time on Market and Market Share

Abstract

Authors

V Heitlage JF Farley R Shah H Tyagi D Stenehjem

Full Text Cite This Article

Back to Volume 25, Supplemental Issue 7S

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now